Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...

We recently published 10 Stocks With Eye-Popping Double-Digit Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

In a bid to create an affordable and accessible healthcare system in Delhi, Chief Minister Rekha Gupta on Thursday launched ...

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and safety concerns.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

HIMS accelerates its global push with the ZAVA acquisition and a planned Canada launch targeting affordable obesity care.

The more cautious voices point to Hims’s high P/E ratio and recent volatility, warning that the stock could cool off after its sharp run-up. That said, a few analysts are still pretty optimistic. They ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...